Oral Dissolving Film Manufacturing at GMP Standard
Author: Sihan Meng, Leyu Zhu, Pengcheng Shi
Affiliation: RSBM
Email: pengchengshi@biotechrs.com; pcspc9@gmail.com
Abstract
Oral dissolving films (ODFs) are increasingly adopted across pharmaceutical and nutraceutical sectors due to their rapid disintegration, precise dosing, and high patient compliance. As ODF products transition from laboratory development to commercial distribution, Good Manufacturing Practice (GMP) compliance becomes a critical determinant of quality, safety, and regulatory acceptance. This paper examines ODF manufacturing under GMP standards, focusing on facility requirements, process control, quality systems, and validation strategies. By aligning formulation science with GMP-oriented manufacturing design, robust and scalable ODF production can be achieved while meeting global regulatory expectations.
Keywords: Oral dissolving film, GMP manufacturing, quality assurance, process validation, regulatory compliance
Introduction
Oral dissolving films represent a patient-centric dosage form that dissolves rapidly in the oral cavity, enabling buccal or sublingual absorption [1]. Compared with conventional tablets or capsules, ODFs offer advantages in onset time, ease of administration, and dosing flexibility. These attributes have driven growing interest in ODF products for prescription, over-the-counter, and wellness applications.
However, the thin-film nature of ODFs introduces unique manufacturing challenges, including sensitivity to moisture, variability in thickness, and the need for precise content uniformity. GMP-compliant manufacturing is therefore essential to ensure consistent quality and regulatory readiness as ODF products move toward commercialization [2]. This paper discusses the key principles and practices of ODF manufacturing at GMP standard.
Methods
A technical and regulatory review methodology was employed. Peer-reviewed literature, pharmacopeial standards, and regulatory guidance documents were analyzed alongside industrial manufacturing practices. The manufacturing workflow was evaluated across raw material handling, solution preparation, film casting, drying, cutting, and packaging. Particular emphasis was placed on GMP elements such as environmental control, documentation, validation, and quality management systems.
Measures
GMP-compliant ODF manufacturing performance was assessed using the following measures:
Environmental control – monitoring of temperature, humidity, and particulate levels in production areas [3].
Process reproducibility – consistency of film thickness, weight, and mechanical properties across batches [4].
Content uniformity – analytical verification of dose accuracy within and between film units [5].
Cleaning and cross-contamination control – validated cleaning procedures for equipment and facilities [6].
Documentation and traceability – batch records, deviation management, and change control systems [7].
Results
Implementation of GMP standards in ODF manufacturing significantly improves batch consistency and regulatory confidence. Controlled environments with defined humidity limits reduce film brittleness and variability, while standardized operating procedures ensure reproducible coating and drying performance [4].
Validated analytical methods confirm content uniformity and support product release decisions. Facilities operating under GMP demonstrate enhanced readiness for regulatory inspections and reduced risk of quality-related recalls during commercial production [5,7].
Discussion
Manufacturing ODFs at GMP standard requires integration of material science, process engineering, and quality systems. Unlike conventional solid dosage forms, ODFs demand tighter environmental and process controls due to their thin structure and moisture sensitivity.
Early incorporation of GMP principles during process design simplifies scale-up and validation. Automated equipment, in-line monitoring, and comprehensive documentation further strengthen compliance and operational efficiency. As regulatory scrutiny increases globally, GMP-standard manufacturing will remain a prerequisite for sustainable ODF commercialization [6,8].
Conclusion
GMP-standard manufacturing is fundamental to the successful commercialization of oral dissolving film products. By implementing controlled environments, validated processes, and robust quality systems, manufacturers can ensure consistent product quality, regulatory compliance, and patient safety. Establishing GMP-aligned ODF manufacturing capabilities supports long-term scalability and global market access for next-generation oral delivery systems.
References
Dixit RP, Puthli SP. Oral strip technology: Overview and future potential. J Control Release. 2009;139(2):94–107.
Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299–316.
European Medicines Agency. EU Guidelines for Good Manufacturing Practice. EMA; 2022.
Preis M, Knop K, Breitkreutz J. Mechanical and process properties of orodispersible films. Int J Pharm. 2014;461(1–2):22–29.
USP <905> Uniformity of Dosage Units. United States Pharmacopeia; 2023.
FDA. Guidance for Industry: Process Validation—General Principles and Practices. U.S. Food and Drug Administration; 2011.
World Health Organization. WHO Technical Report Series: Good Manufacturing Practices. WHO; 2020.
Krampe R, Breitkreutz J. Manufacturing and regulatory considerations for oromucosal films. Pharm Dev Technol. 2017;22(2):195–204.